• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Veru’s obe­si­ty drug rough­ly as safe as We­govy; Keros’ board fight

Last month
News Briefing

A new dawn for psy­che­delics? Com­pass could be the first to find out

Last month
Pharma
In Focus

Post-Hoc Live: Is biotech sen­ti­ment re­al­ly as bad as it seems? 

Last month
Financing
Deals

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

Last month
R&D

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

Last month
Financing
Startups

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

Last month
R&D

Ax­some and Het­ero set­tle patent fight over sleep dis­or­der drug

Last month
Pharma
Law

No­var­tis won bid­ding war for kid­ney drug as Reg­u­lus' top three ex­ecs ex­pect to make over $100M com­bined

Last month
Deals

FDA lead­er­ship preps for sum­mer bio­phar­ma lis­ten­ing tour across six cities

Last month
FDA+

FDA re­jects Savara’s rare lung dis­ease drug over lim­it­ed man­u­fac­tur­ing da­ta

Last month
Pharma
FDA+

Ser­no­va chair re­signs fol­low­ing in­sid­er trad­ing in­dict­ment over No­var­tis-Chi­nook deal

Last month
People
Law

Bound­less Bio changes plans for can­cer drug af­ter tox­i­c­i­ty is­sues

Last month
People
R&D

RFK Jr. ends an­nu­al Covid vac­cine rec­om­men­da­tions for kids, preg­nant women

Last month
FDA+

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

Last month
Deals
Pharma

Liq­uidia wins ap­proval for in­haled hy­per­ten­sion drug in two set­tings, fur­ther­ing ri­val­ry with Unit­ed Ther­a­peu­tics

Last month
Pharma
FDA+

ITM re­veals up to $262M debt fi­nanc­ing; Caris Life Sci­ences to go pub­lic

Last month
News Briefing

Gil­gamesh’s short-act­ing psy­che­del­ic drug shows rapid ef­fect in Phase 2 de­pres­sion study

Last month
R&D

Bio­gen taps City Ther­a­peu­tics in RNAi deal worth up to $1B

Last month
Startups
Deals

Brook­lyn Health rais­es $6.5M to stan­dard­ize men­tal health as­sess­ment

Last month
Financing
Health Tech

Black­stone's GRIN inks epilep­sy li­cens­ing deal with An­geli­ni, clos­es $140M Se­ries D

Last month
Deals
Pharma

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Last month
Cell/Gene Tx
FDA+

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

Last month
People
R&D

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

Last month
Financing
Startups

Syn­deio de­buts with $90M+ to bring to­geth­er synapse re­pair drugs

Last month
Financing
First page Previous page 14151617181920 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times